We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 62% below its sector, cheaper than its peers on earnings.
China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele encompasses hospitals, retail pharmacies, and other healthcare organizations. Established in 1999, the company maintains its principal office in Beijing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 600511.SS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
